Potent ex vivo armed T cells using recombinant bispecific antibodies for adoptive immunotherapy with reduced cytokine release
Jeong A Park(Inha University Hospital), Nai‐Kong V. Cheung(Memorial Sloan Kettering Cancer Center)
Cited by 47
Related Papers
Biology of childhood osteogenic sarcoma and potential targets for therapeutic development: meeting summary.
|PubMed|2003|198
Retargeting T Cells to GD2 Pentasaccharide on Human Tumors Using Bispecific Humanized Antibody
|Cancer Immunology Research|2014|97
GD2 or HER2 targeting T cell engaging bispecific antibodies to treat osteosarcoma
|Journal of Hematology & Oncology|2020|86
Interdomain spacing and spatial configuration drive the potency of IgG-[L]-scFv T cell bispecific antibodies
|Science Translational Medicine|2020|83